| HOU Jun,FENG Lin-chun,CAI Bo-ning,et al.Clinical observation in nasopharyngeal carcinoma (NPC) treated with the anti-EGFR monoclonal antibody followed by helical tomotherapy[J].Chinese Journal of Radiological Medicine and Protection,2011,31(3):329-332 |
| Clinical observation in nasopharyngeal carcinoma (NPC) treated with the anti-EGFR monoclonal antibody followed by helical tomotherapy |
| Received:January 22, 2011 |
| DOI：10.3760/cma.j.issn.0254-5098.2011.03.020 |
| KeyWords:Tomotherapy Nasopharyngeal carcinoma Nimotuzumab Cetuximab |
| FundProject: |
| Author Name | Affiliation | | HOU Jun | Department of Radiation Oncology, PLA General Hospital, Beijing 100853, China | | FENG Lin-chun | Department of Radiation Oncology, PLA General Hospital, Beijing 100853, China | | CAI Bo-ning | Department of Radiation Oncology, PLA General Hospital, Beijing 100853, China | | LU Na | Department of Radiation Oncology, PLA General Hospital, Beijing 100853, China | | DU Lei | Department of Radiation Oncology, PLA General Hospital, Beijing 100853, China | | MA Lin | Department of Radiation Oncology, PLA General Hospital, Beijing 100853, China | | XU Shou-ping | Department of Radiation Oncology, PLA General Hospital, Beijing 100853, China | | XIE Chuan-bin | Department of Radiation Oncology, PLA General Hospital, Beijing 100853, China |
|
| Hits: 3511 |
| Download times: 2855 |
| Abstract:: |
| Objective To evaluate the clinical outcome and the acute toxicity in nasopharyngeal carcinoma (NPC) treated with tomotherapy followed by the anti-EGFR monoclonal antibody. Methods Between March 2008 and November 2009, 34 newly diagnosed NPC patients were treated with helical tomotherapy combined with nimotuzumab or cetuximab. All the patients underwent tomotherapy at the dose of 70 Gy/33F for the gross tumor volume (pGTVnx) and positive lymphnodes (GTVnd), and 60 Gy/33F for the high risk clinical target volume (PTV1), and 56 Gy/33F for the low risk clinical target volume (PTV2), respectively. 17 patients in group N were given weekly injection of 200 mg for 6-7 times and 17 patients in group C were given initial dosage 400 mg/m2 followed by subsequent weekly dosage of 250 mg/m2 for 6-7 times. Acute lesions were evaluated with the RTOG/EORTC criteria. Result The median follow-up time was 22 months. The effective rates (CR+PR) in 3, 6 and 12 months were 14/17, 12/17, 12/17 in group N and 15/17, 14/17, 14/17 in group C. The 1 year survival rate was 15/17 in group N and 17/17 in group C. Nimotuzumab had less acute mucositis reaction (u=2.25, P<0.05), weight loss (t=2.56, P=0.02) and rash (u=4.36, P<0.01) compared with cetuximab. Conclusions Helical tomotherapy combined with nimotuzumab or cetuximab was effective and made no difference in the short-term efficacy and 1 year survival rate for the patients with NPC. Nimotuzumab has less acute reaction than cetuximab. More studies should be done to prove long-term effects. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
